Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Global developmental delay and postnatal microcephaly: Bainbridge-Ropers syndrom...
Journal Information
Vol. 33. Issue 7.
Pages 484-486 (September 2018)
Vol. 33. Issue 7.
Pages 484-486 (September 2018)
Letter to the Editor
DOI: 10.1016/j.nrleng.2017.01.005
Open Access
Global developmental delay and postnatal microcephaly: Bainbridge-Ropers syndrome with a new mutation in ASXL3
Retraso global del desarrollo y microcefalia posnatal: síndrome de Bainbridge-Ropers con una nueva variante de novo en ASXL3
Visits
...
S.N. Contreras-Capetilloa,
Corresponding author
silvina.contreras@uady.mx

Corresponding author.
, Z.H. Vilchis-Zapataa, J. Ribbón-Condeb, D. Pinto-Escalantea
a Laboratorio de Genética, Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Mérida, Yucatán, Mexico
b Departamento de Neurología Pediátrica, Hospital General Regional #1, Instituto Mexicano del Seguro Social, Mérida, Yucatán, Mexico
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Comparison of the clinical characteristics of patients with Bainbridge-Ropers syndrome with variants of the ASXL3 gene and patients with Bohring-Opitz syndrome.
Full Text
Dear Editor:

Exomic sequencing reveals genetic syndromes in up to 25% of subjects with genetic diseases which remain undiagnosed after multiple genetic studies.1,2 In 2013, Bainbridge and Ropers reported de novo variants of truncating mutations of the Additional sex combs-like 3 gene (ASXL3, locus 18q12.2, 12 exons) in 4 patients with severe psychomotor retardation, and learning and feeding difficulties.3

We examined a 3-year-old boy, who was the fourth child of healthy, non-consanguineous Mexican parents. The other 3 children were healthy. He was delivered vaginally after a normal, full-term pregnancy (length: p > 97; weight: p > 85; head circumference: p97; Apgar score: 7.9). He achieved head control at 6 months and could sit at one year. At 36 months of age, the patient presented severe neurodevelopmental delay and was unable to speak or walk. He also presented microcephaly (−4.35SD), short stature (−3.5SD), and poor weight gain (−4.6SD). The facial phenotype included prominent forehead, hypertelorism, high anterior hairline, thin eyebrows, mild synophrys, anteverted nostrils with hypoplastic alae nasi, high-arched palate, and low-set prominent ears. We also observed fingertip pads, broad thumb and big toe in both hands and feet, and cryptorchidism (Fig. 1). A brain MRI scan revealed cortical atrophy. Karyotyping (46, XY) and comparative genomic hybridisation (400k) yielded normal results. Baylor Miraca Genetics Laboratories performed whole exomic sequencing from purified genomic DNA extracted from the patient's peripheral blood. Sequencing consisted in DNA fragmentation by sonication and ligation with multiplex sequencing adapters on the Illumina platform.4 The process of enrichment/capture was performed by hybridisation of a microarray customised by NimbleGen (VCRome 2.1),5 as well as additional probes for 3650 Mendelian and mitochondrial genome genes.6 We used the Illumina HiSeq 2000 system for analysis (median exome coverage, 95%; median nucleotide coverage, >100×). Variant calling and annotations were performed using the Atlas-SNP/SNP-anno and Atlas-indel/HGSC-anno tools, developed in-house by Baylor College of Medicine. De novo variants and in silico predictions of nonsense changes were reported according to the American College of Medical Genetics criteria.7 The patient was heterozygous for a 4-bp deletion on chromosome 18:31320359 at NM_030632.2 (ASXL3): c.2992-2995del, p.(E998fs) in exon 11; this frameshift mutation causes an aberrant protein, predicted to be deleterious. Sanger sequencing of the ASXL3 gene in the patient's parents yielded normal results; therefore, we believe this to be a de novo variant in the proband.

Figure 1.

Clinical phenotype: (A and B) Wide forehead, prominent metopic ridge, permanently open mouth, and low-set ears with posterior rotation. (C) Fingertip pads. (D and E) Broad fingers and toes, especially the thumb and toe.

(0.14MB).

Few patients with Bainbridge-Ropers syndrome (MIM #615485) have been reported to date. Diagnosis is achieved after whole-genome and exome sequencing, since the phenotype is subtle and variable.3,8–11 The common clinical characteristics (severe psychomotor retardation, facial dysmorphism, growth failure, and feeding difficulties) can be misinterpreted as such other syndromes as Bohring-Opitz syndrome (MIM #605039) (Table 1).12,13 Bohring-Opitz syndrome is related to genetic variants of ASXL1, and no variants of ASXL3 have been detected; these syndromes are therefore considered 2 distinct entities.3,12 Most of the described variants of ASXL3 are de novo mutations producing premature stop codons or shifting the reading frame in the coding region of the ASXL3 gene, and group together in a region of exon 11.3,8,9 Bainbridge-Ropers syndrome represents a challenge for molecular diagnosis based on the analysis of a single gene or multiple-gene panel testing; therefore, the recent introduction of whole-genome or exome sequencing techniques is useful for research into the aetiology of neurodevelopmental disorders.

Table 1.

Comparison of the clinical characteristics of patients with Bainbridge-Ropers syndrome with variants of the ASXL3 gene and patients with Bohring-Opitz syndrome.

Phenotype  Bainbridge et al.3 (2013), Dinwiddie et al.8 (2013), Hori et al.10 (2016), Srivastava et al.11 (2016)  Present study  BOS, Hastings et al.12 (2011) 
Prenatal
Intrauterine growth restriction  5/9  No  11/14 
Neurological
Global developmental delay  9/9  Yes  14/14 
Hypotonia  8/9  Yes  7/14 
Feeding difficulty  8/9  Yes  14/14 
Language delay  6/9  Yes  – 
Seizures  2/9  Yes  – 
Craniofacial
Microcephaly  5/9  Yes  14/14 
Prominent forehead  5/9  Yes  – 
Arched eyebrows  5/9  Yes  – 
Hypertelorism  1/9  Yes  9/14 
Anteverted/hypoplastic nostrils  6/9  Yes  8/14 
Low-set ears with posterior rotation  6/9  Yes  8/14 
Typical BOS posture  0/9  No  14/14 

BOS: Bohring-Opitz syndrome.

Acknowledgements

We would like to thank our patient's family for their interest in sharing his case for scientific research purposes.

References
[1]
Y. Yang, D.M. Muzny, J. Reid, M. Bainbridge, A. Willis, P.A. Ward, et al.
Clinical whole-exome sequencing for the diagnosis of mendelian disorders.
N Engl J Med, 369 (2013), pp. 1502-1511
[2]
H. Lee, J.L. Deignan, N. Dorrani, S.P. Strom, S. Kantarci, F. Quintero-Rivera, et al.
Clinical exome sequencing for genetic identification of rare mendelian disorders.
JAMA, 312 (2014), pp. 1880-1887
[3]
M.N. Bainbridge, H. Hu, D.M. Muzny, L. Musante, J.R. Lupski, B.H. Graham, et al.
De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome.
Genome Med, 5 (2013), pp. 11
[4]
Illumina, Inc..
Multiplexing Sample Preparation Guide (Part # 1005361 Rev. D).
(2011),
[5]
Roche NimbleGen, Inc..
NimbleGen SeqCap EZ Exome Library SR User's Guide (Version 2.2).
(2010),
[6]
M.N. Bainbridge, M. Wang, Y. Wu, I. Newsham, D.M. Muzny, J.L. Jefferies, et al.
Targeted Enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities.
Genome Biol, 12 (2011), pp. 12
[7]
C.S. Richards, S. Bale, D.B. Bellissimo, S. Das, W.W. Grody, M.R. Hegde, Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee, et al.
ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007.
Genet Med, 10 (2008), pp. 294-300
[8]
D.L. Dinwiddie, S.E. Soden, C.J. Saunders, N.A. Miller, E.G. Farrow, L.D. Smith, et al.
De novo frameshift mutation in ASXL3 in a patient with global developmental delay, microcephaly, and craniofacial anomalies.
BMC Med Genomics, 6 (2013), pp. 6-32
[9]
X. Zhu, S. Petrovski, P. Xie, E.K. Ruzzo, Y.F. Lu, K.M. McSweeney, et al.
Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios.
Genet Med, 17 (2015), pp. 774-781
[10]
I. Hori, F. Miya, K. Ohashi, Y. Negishi, A. Hattori, N. Ando, et al.
Novel splicing mutation in the ASXL3 gene causing Bainbridge-Ropers syndrome.
Am J Med Genet Part A, 170 (2016), pp. 1863-1867
[11]
A. Srivastava, K.C. Ritesh, Y.C. Tsan, R. Liao, F. Su, X. Cao, et al.
De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome.
Hum Mol Genet, 25 (2016), pp. 597-608
[12]
R. Hastings, J.M. Cobben, G. Gillessen-Kaesbach, J. Goodship, H. Hove, S. Kjaergaard, et al.
Bohring-Opitz (Oberklaid-Danks) syndrome: clinical study, review of the literature, and discussion of possible pathogenesis.
Eur J Hum Genet, 19 (2011), pp. 513-519
[13]
A. Hoischen, W.M. van Bon Bregje, B. Rodríguez-Santiago, C. Gilissen, L.E.L. Vissers, P. de Vries, et al.
De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome.
Nat Genet, 43 (2011), pp. 729-731

Please cite this article as: Contreras-Capetillo SN, Vilchis-Zapata ZH, Ribbón-Conde J, Pinto-Escalante D. Retraso global del desarrollo y microcefalia posnatal: síndrome de Bainbridge-Ropers con una nueva variante de novo en ASXL3. Neurología. 2018;33:484–486.

This study was presented as a free paper in poster format at the 40th National Congress of Human Genetics in Monterrey (Nuevo León, Mexico), 11–14 November 2015.

Copyright © 2017. Sociedad Española de Neurología
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.